Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Koninklijke Philips NV is the Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.

  • Revenue in USD (TTM)19.62bn
  • Net income in USD-510.13m
  • Incorporated2000
  • Employees69.28k
  • Location
    Koninklijke Philips NVHigh Tech Campus 5EINDHOVEN 5656 AENetherlandsNLD
  • Phone+31 205977777
  • Fax+31 205977220
  • Websitehttps://www.philips.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Revvity Inc2.72bn258.26m15.39bn11.50k59.591.9422.425.662.092.0622.0664.230.20782.894.37236,657.001.974.762.155.3955.4457.199.4915.342.9712.430.28696.52-16.95-0.1982-64.99-5.28-2.690.00
Align Technology, Inc.3.96bn441.57m15.74bn21.61k35.933.9936.753.985.875.8752.6352.800.62454.324.14183,272.506.9616.3410.3924.1469.9871.7211.1523.161.14----0.003.4214.4523.092.15-4.46--
Insulet Corp1.87bn395.30m16.65bn3.00k43.8716.6735.368.895.415.4124.5314.240.7111.386.25624,233.3015.012.7118.153.1469.0065.8121.114.282.7187.970.58330.0030.0224.664,384.78128.77-7.63--
Baxter International Inc15.00bn-157.00m18.26bn60.00k--2.3916.451.22-0.30664.8729.4814.980.55343.245.73249,950.00-0.54620.1942-0.70190.233336.4838.20-0.98690.36740.91474.250.6261,398.942.125.9497.15--0.9829.71
Hologic Inc3.99bn701.50m19.45bn6.99k28.573.9219.234.882.932.9316.5921.330.43752.646.06570,472.107.7011.408.6413.3855.4160.2917.5920.953.32709.770.34080.00-17.124.61-64.98--7.30--
Cooper Companies Inc3.80bn359.30m20.88bn15.00k58.392.6328.375.491.801.8019.0239.800.31961.705.56253,606.703.0210.063.2911.3466.3665.549.4529.001.185.460.24930.34698.617.24-23.74-3.6615.180.00
Zimmer Biomet Holdings Inc7.60bn1.08bn21.58bn18.00k20.651.7510.482.845.255.2536.8762.000.35380.91365.38421,972.205.052.215.822.5271.7871.2514.287.280.69877.520.342538.906.55-1.40252.86--9.440.00
Steris PLC5.13bn567.70m22.27bn18.18k39.473.5120.074.345.724.0351.7364.320.49143.985.77282,395.105.455.195.955.6843.1943.6411.0910.971.497.030.266636.5613.2813.06-1.0712.6713.698.83
West Pharmaceutical Services Inc.2.88bn499.60m22.80bn10.60k46.648.2935.957.936.756.7538.8637.960.77434.505.51271,358.5013.0215.6115.1618.6534.8738.0616.8118.472.23--0.069510.692.1811.432.2823.7628.166.20
Waters Corp2.91bn622.64m22.99bn7.90k36.9614.3428.227.9110.4810.4848.8927.000.6452.204.47367,740.1013.8219.7716.7225.2959.7358.4521.4323.381.3810.110.53250.00-0.52294.09-9.261.534.72--
Illumina Inc4.39bn-1.58bn24.45bn10.59k--11.51--5.57-10.00-10.0027.6113.340.54412.666.24414,542.00-19.63-6.20-23.16-7.2863.9466.39-36.08-15.481.85--0.4834---1.756.2173.64---7.91--
Koninklijke Philips NV (ADR)19.62bn-510.13m25.48bn69.28k----33.271.30-0.566-0.403121.00--------281,684.90--0.3678--0.501342.1843.84-2.590.6049--5.35--447.231.920.052971.87---5.24--
DexCom Inc3.95bn680.80m27.22bn9.60k42.5513.7630.486.891.641.649.525.070.61072.764.42411,875.0010.518.3014.2810.5062.1065.9017.2214.142.12--0.55790.0024.4928.5658.70--28.66--
IDEXX Laboratories, Inc.3.84bn866.24m33.94bn11.00k39.9921.0234.218.8310.3610.3646.0019.721.193.857.14349,528.8026.9128.0038.8643.4960.7258.7422.5321.351.0359.100.35070.008.7210.5924.4417.391.68--
Veeva Systems Inc2.57bn615.26m34.42bn7.17k55.146.6352.8013.373.853.8515.6932.040.4453--6.27358,846.8010.6511.9712.9715.3673.3572.0023.9123.74----0.000.009.6822.357.7918.0021.68--
Data as of Nov 05 2024. Currency figures normalised to Koninklijke Philips NV's reporting currency: US Dollar USD

Institutional shareholders

3.87%Per cent of shares held by top holders
HolderShares% Held
Mondrian Investment Partners Ltd.as of 30 Jun 20248.18m0.87%
Fiduciary Management, Inc.as of 30 Jun 20246.70m0.71%
Dimensional Fund Advisors LPas of 30 Jun 20243.90m0.42%
BlackRock Investment Management LLCas of 30 Jun 20243.89m0.41%
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 20243.01m0.32%
Fidelity Management & Research Co. LLCas of 30 Jun 20242.78m0.30%
Strategic Advisers LLCas of 30 Jun 20242.70m0.29%
Thompson, Siegel & Walmsley LLCas of 30 Jun 20241.93m0.21%
Parametric Portfolio Associates LLCas of 30 Jun 20241.79m0.19%
Envestnet Asset Management, Inc.as of 30 Jun 20241.53m0.16%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.